Literature DB >> 22234091

Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer.

Seyed Hamid Madani1, Somayeh Ameli, Sedigheh Khazaei, Malek Kanani, Babak Izadi.   

Abstract

CONTEXT: Prostate cancer is the most common malignant tumor in men. Tumor grade is one of the most important prognostic factors of prostate cancer. P53 and Ki-67 expressions have also been considered to be prognostic factors. AIMS: This study was performed to investigate the frequency of these proteins expression and compare the obtained results with Gleason's grading. SETTINGS AND
DESIGN: In this cross-sectional study, 49 paraffin blocks of prostate cancers were assessed. Tumor grade was determined according to the Gleason's criteria.
MATERIALS AND METHODS: Ki-67 and P53 expressions were determined by immunohistochemical staining. STATISTICAL ANALYSIS: The obtained results were analyzed and evaluated using Spearman's statistical test (SPSS version 15).
RESULTS: Three out of 49 (6.1%) cases were well differentiated, 21 (43%) moderately differentiated and 25 (51%) were poorly differentiated. P53 was negative in all well-differentiated cases. Ki-67 was negative in 14 cases (28%) including all well-differentiated tumors. Among moderately and poorly differentiated tumors Ki-67 was negative in eight (38%) and three (12%) of cases, respectively. A statistically significant relation was observed between the increased Ki-67 labeling index (LI) and increased Gleason's grade. Conversely, no statistically significant relation was found between P53 expression and increased Gleason's grade.
CONCLUSIONS: According to the findings of this study, it seems that Ki-67 can be used as a prognostic factor for prostate cancer. On the other hand, the probable relation between P-53 and prostate cancer prognosis requires further studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22234091     DOI: 10.4103/0377-4929.91492

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  8 in total

Review 1.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

2.  Expression of estrogen receptor β and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry.

Authors:  Shrruti K Grover; Sarla Agarwal; Sanjay Gupta; Neelam Wadhwa; Nivedita Sharma
Journal:  Pathol Oncol Res       Date:  2014-12-20       Impact factor: 3.201

3.  Intraperitoneal Injection of Graphene Oxide Nanoparticle Accelerates Stem Cell Therapy Effects on Acute Kidney Injury.

Authors:  Tahereh Foroutan; Mohsen Nafar; Elaheh Motamedi
Journal:  Stem Cells Cloning       Date:  2020-02-11

4.  Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.

Authors:  Steven M Lucas; Elisabeth I Heath
Journal:  Prostate Cancer       Date:  2012-08-28

5.  The effects of phenoxodiol on the cell cycle of prostate cancer cell lines.

Authors:  Simon Mahoney; Frank Arfuso; Michael Millward; Arun Dharmarajan
Journal:  Cancer Cell Int       Date:  2014-11-08       Impact factor: 5.722

6.  Significance of p53 and ki-67 expression in prostate cancer.

Authors:  Renuka Verma; Veena Gupta; Jagjeet Singh; Monica Verma; Gopal Gupta; Sumiti Gupta; Rajeev Sen; Megha Ralli
Journal:  Urol Ann       Date:  2015 Oct-Dec

7.  Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis.

Authors:  Cristina-Anita Ionescu; Mariana Aschie; Elena Matei; Georgeta Camelia Cozaru; Mariana Deacu; Anca Florentina Mitroi; Gabriela Isabela Baltatescu; Antonela-Anca Nicolau; Laura Mazilu; Liliana Ana Tuta; Ionut Ciprian Iorga; Alina Stanigut; Manuela Enciu
Journal:  Biomedicines       Date:  2022-07-12

Review 8.  Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Authors:  Tamara Sequeiros; Marta García; Melania Montes; Mireia Oliván; Marina Rigau; Eva Colás; Inés de Torres; Juan Morote; Jaume Reventós; Andreas Doll
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.